Ethosuximide

CLINICAL USE


Epilepsy

DOSE IN NORMAL RENAL FUNCTION

500 mg – 2 g daily in divided doses

PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :141.2
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :01
  • %Excreted unchanged in urine &nbsp &nbsp : 12–20

  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp :0.6–0.9

  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :40–60/Unchanged

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Dialysed. Dose as in normal renal function

  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed. Dose as in normal renal function
  • HDF/high flux &nbsp :Dialysed. Dose as in normal renal function
  • CAV/VVHD &nbsp &nbsp &nbsp:Dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
  • Antibacterials: concentration increased by isoniazid
  • Antidepressants: lower convulsive threshold
  • Anti-epileptics: concentration possibly reduced by carbamazepine, phenytoin and primidone; concentration of phenytoin possibly increased; concentration increased by valproate
  • Antimalarials: possibly increased risk of convulsions with chloroquine and hydroxychloroquine; anticonvulsant effect antagonised by mefloquine
  • Antipsychotics: lower convulsive threshold

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    –

    OTHER INFORMATION


    Tags:

    • Related News

    sotalol hydrochloride.txt

    tazocin.txt